Multidrug-Resistant Tuberculosis: Tools for Tackling a New Face of an Old Foe
Presented on .
Tuberculosis is an ancient disease that remains an important global cause of morbidity and mortality. In most cases, TB can be treated and cured by taking a combination of several drugs for 6 to 12 months. When inappropriate or incomplete treatment takes place, however, TB bacteria can develop resistance to multiple drugs. Treatment of drug-resistant TB is currently longer, more toxic, more complex, and less effective than for drug-susceptible TB. In 2011, less than 10% of the total estimated multidrug-resistant TB (MDR TB) cases were detected and annually, there are approximately 500,000 cases of MDR TB, and 150,000 deaths. Although there are simple rapid tests that have improved the diagnosis of the disease, there is immense potential to increase the number of persons diagnosed with MDR TB, and diagnose them more quickly so that they can begin treatment sooner.
In this session we discussed how more patients can benefit from advances in diagnostic and treatment options, resulting in an overall reduction in morbidity from MDR TB. This session of Grand Rounds also explored the role of CDC, WHO and other partners in combating this public health epidemic.
Dr. John Iskander and Dr. Sarita Shah discuss the public health burden of multidrug-resistant tuberculosis (MDR TB) and the new tools that are available for more accurate diagnosis and treatment of MDR TB. Revolutionary tests will allow for faster diagnosis and new drugs offer better treatment with fewer side effects, but patients and providers must also do their part to combat this health epidemic.
Patients must:
- Come to their providers in a timely fashion and
- Complete the full course of treatment
Providers must:
- Improve diagnosis and treatment of drug susceptible TB and
- Emphasize proper Infection control practices
- Sarita Shah, MD, MPH
- Associate Chief for Science, International Research and Programs Branch, Division of TB Elimination
National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC
- Thomas M. Shinnick, PhD
- Associate Director for Global Laboratory Activities, Division of TB Elimination
National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC
- Christian Lienhardt, MD, PhD, MSc
- Senior Research Advisor, Global TB Program
World Health Organization
- Tom Kenyon, MD, MPH
- Director
Center for Global Health, CDC
- Darlene Von Delft, MBChB
- Emergency Medicine Doctor
Mediclinic Vergelegen Hospital
- John Iskander, MD, MPH
- Scientific Director
- Susan Laird, MSN, RN
- Communications Director
Get notified about the latest updates from Public Health Grand Rounds right in your inbox by setting up an alert today!
Get notified about the latest updates from Public Health Grand Rounds right in your inbox by setting up an alert today!Sign Up
Get notified about the latest updates from Public Health Grand Rounds right in your inbox by setting up an alert today!
Tuberculosis (TB) still remains a serious threat, especially for those infected with HIV. HIV is the single most powerful risk factor for TB disease and one of the leading causes of death among people infected with HIV. Learn about TB and HIV and hear what is needed to prevent deaths from this lethal combination.
When it comes to tracking infectious diseases and outbreaks, determining who is infected with a particular pathogen is the first step. Newer tests are making these determinations faster, but they lack crucial information. Hear about the challenges and promises of the changing landscape of diagnosing infectious diseases.